Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass-Reference-Cited by-同舟云学术

Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass

Published:2016-09-20 Issue:1 Volume:32 Page:181-187
ISSN:0884-0431
Container-title:Journal of Bone and Mineral Research
language:en
Short-container-title:J Bone Miner Res

Author:

Genant Harry K¹²,Engelke Klaus³⁴,Bolognese Michael A⁵,Mautalen Carlos⁶,Brown Jacques P⁷,Recknor Chris⁸,Goemaere Stefan⁹,Fuerst Thomas¹⁰,Yang Yu-Ching¹¹,Grauer Andreas¹¹,Libanati Cesar¹²

Affiliation:

1. University of California; San Francisco (UCSF); San Francisco CA USA

2. BioClinica-Synarc; San Francisco CA USA

3. BioClinica; Hamburg Germany

4. Institute of Medical Physics; University of Erlangen; Erlangen Germany

5. The Bethesda Health Research Center; Bethesda MD USA

6. Centro de Osteopatias Medicas; Buenos Aires Argentina

7. CHU de Québec Research Centre and Laval University; Québec QC Canada

8. United Osteoporosis Centers; Gainesville GA USA

9. Department of Endocrinology and Unit for Osteoporosis and Metabolic Bone Diseases, Ghent University Hospital; Ghent Belgium

10. BioClinica Inc.; Newark CA USA

11. Amgen Inc.; Thousand Oaks CA USA

12. UCB BioPharma; Brussels; Belgium

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jbmr.2932/fullpdf

Reference26 articles.

1. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis;Li;J Bone Miner Res,2009

2. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats;Li;J Bone Miner Res,2010

3. Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study;Padhi;J Clin Pharmacol,2014

4. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody;Padhi;J Bone Miner Res,2011

5. Romosozumab in postmenopausal women with low bone mineral density;McClung;N Engl J Med,2014

Cited by 112 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate on cortical and trabecular bone of vertebra and proximal femur in postmenopausal women with fragility fracture: Sub-analysis by quantitative computed tomography from the TERABIT study;Bone;2024-10

2. Treatment effects, adverse outcomes and cardiovascular safety of romosozumab – Existing worldwide data: A systematic review and meta-analysis;Journal of Orthopaedic Translation;2024-09

3. The potential effect of romosozumab on perioperative management for instrumentation surgery;JOR SPINE;2024-08-05

4. The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal Women With Osteoporosis;The Journal of Clinical Endocrinology & Metabolism;2024-07-16

5. Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis;Journal of Bone and Mineral Metabolism;2024-07-15